News

A review of more than 1,000 studies found the vast majority of economic analyses of HCV therapies don’t incorporate patient input.

Nursing home communities can theoretically improve health outcomes for patients with antibiotic stewardship programs.

If approved, the drug could open a new line of treatment for people struggling to control symptoms despite drug therapy.

The reSET app is the first mobile medical application to treat substance use disorders.

The long-term study shows biosimilar adalimumab, if approved, will further improve access to treatment for immunological diseases.

The FDA approved the inhaler treatment based on 2 Phase III-B studies running 6 months and 12 months, respectively, to compare the drug’s efficacy in COPD exacerbation care.

The study authors theorized that there are further connections between age and HA, with older adults having significantly more HA than younger adults.

The genomes associated with a higher risk of CHD are also associated with higher T2D risk, revealing the possibility of a treatment for both.

The influenza virus triggered multiple sclerosis relapses in mice models.

Direct-acting antiviral sofosbuvir has had a high success rate in treating chronic HCV. But the potential for toxicity to the kidneys has raised some concern, especially in patients with CKD.

An expert advisory board voted 11-0 in confidence of the vaccine's safety and efficacy trial data Wednesday.

The drug is the first and only fully-human antagonist showing sustained skin clearance rates at 5 years.

The study identified the CYP-derived lipid biometabolites and determined that they help reduce inflammation within CNV lesions.

Researchers investigated the association between D2 and D3 receptor availability in the striatum and cognitive function in adults with major depressive disorder.

Sanofi’s dual SGLT1 and SGLT2 inhibitor was statistically significantly superior to placebo in patients with type 1 diabetes (T1D) on background insulin therapy.

A Seattle company is hoping its technology will help drug companies more efficiently test out the safety and efficacy of drugs that must cross the blood-brain barrier.

Mirebegron is already approved as a monotherapy for OAB with symptoms of urgency and urinary frequency, and urge urinary continence The drug's review date was set for April 28, 2018.

A substance known as epicatechin monomers helps the body release more insulin and respond more efficiently to increased blood glucose, which could in turn benefit type 2 diabetics.

Researchers trying to unpack the benefits of omega-3 fatty acids were able to trigger a process that appears to reduce inflammation and could be beneficial to patients with MS.

A highly effective antipsychotic with no major motor side effects is needed.

The BARDA contract funds a specified portion of estimated costs related to the drug’s development.

A triple combination of hepatitis C agents administered with another manufacturer's direct acting antiviral overcomes most difficult-to-cure Genotype 3.

Patients in the combination arm also reached the target HbA1c level faster than those using just the single treatment therapy.

Inhaled corticosteroid for wheezing in early childhood is effective in selected patients but does not prevent progression to asthma.

The use of MHW is reportedly highest in younger females with higher levels of education.

Previous guidelines indicated bypass surgery is preferable for diabetics generally, but new research sought to find out if the same held true for the relatively small number of type 1 diabetics.

The study showed positive results in a difficult-to-treat patient population.

Johnson & Johnson's pharmaceuticals company is discontiuing pursuits of triple-combination treatment JNJ-4178.

Women with type 1 diabetes carry a higher risk of AFib than both men and the general public as a whole.

About one million US adults and adolescents live with uncontrolled, persistent asthma — despite there already being an intensive regimen of standard therapies. Dupilumab may be a missing piece to comprehensive treatment.